摘要
目的 探讨孟鲁司特对咳嗽变异性哮喘患儿血清白细胞介素-13 (IL-13)与白细胞介素-18 (IL-18)的影响.方法 92例咳嗽变异性哮喘患儿随机分为两组,观察组46例和对照组46例,对照组采用糖皮质激素治疗,观察组在糖皮质激素治疗基础上加用孟鲁司特.IL-13与IL-18在治疗前后被检测.结果 观察组总有效率为95.7%,对照组总有效率为86.9%,两组比较差异有统计学意义(P<0.05).观察组治疗后IL-13与IL-18均有明显改善,与对照组比较差异有统计学意义(P<0.01).两组在治疗后IL-18/IL-13均升高,两组比较观察组升高更明显(P<0.05).结论 孟鲁司特可能通过改善IL-13与IL-18平衡而改善咳嗽变异性哮喘患儿的病情.
Objective To investigate the effect of montelukast on interleukin-13 (IL-13) and interleukin-18 (IL-18) in the serum of children with cough variant asthma(CVA).Methods Ninety-two cases of CVA were randomly devided into control group (46 cases) and observation group (46 cases).The children in the control group were given glucocorticoid and the children in the observation group were given montelukast.The levels of IL-13 and IL-18 in the serum were measured before and after treatment.Results After treatment,the concentration of IL-13 and IL-18 in patients in the observation group were significantly lower than those in the control group (P <0.01).IL-18/IL-13 in patients in the observation group were significantly improved than those in the control group (P < 0.05).Conclusions The treatment of montelukast could improve the CVA through improving the production of IL-18/IL-13.
出处
《中国实用医刊》
2013年第21期43-44,共2页
Chinese Journal of Practical Medicine